1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

The registered record

Accession number

NCT05460611

Lead sponsor

Montefiore Medical Center (other)

Collaborators

Sciton

Registered conditions naming hair loss

Scarring AlopeciaAndrogenetic Alopecia

Official title

A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Interventions

• DeviceSciton HALO 1470nm Non-ablative laser

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Not applicable

Allocation

non randomized

Masking

none

Primary purpose

treatment

Enrolment

10 participants (estimated)

Sites

1 location in United States

What it measures

1. Live and Photographic assessment of hair loss

   Time frame: Month 1 (baseline), Month 2, Month 3, Month 6, Month 9, Month 12, Month 15

2. Hair Density

   Time frame: Month 1 (baseline), and during the four follow-up periods at Month 6, Month 9, Month 12, and Month 15 (i.e., up to 14 months after initial treatment)

3. Hair Counts

   Time frame: Month 1 (baseline), and during the four follow-up periods at Month 6, Month 9, Month 12, and Month 15 (i.e., up to 14 months after initial treatment)

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

18 Years to 99 Years

Healthy volunteers

accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

7 December 2023 (actual)

Primary completion

July 2028 (estimated)

Study completion

July 2028 (estimated)

First posted

15 July 2022 (actual)

Last update posted

11 June 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2028-07 is a month, and rendering it as 1 July 2028 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Scarring Alopecia Types and Management: Complete GuideFrontal Fibrosing Alopecia: Complete Guide to Symptoms, Causes & Treatment (2026)Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best Results

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT05460611 on ClinicalTrials.gov · All 157 trials in the pipeline